33 studies found for: Open Studies | "intraocular melanoma"
|1||Not yet recruiting||
Vorinostat in Patients With Class 2 High Risk Uveal Melanoma
Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma
Intermittent Selumetinib for Uveal Melanoma
Randomized Phase III Study Comparing an Adjuvant Chemotherapy With Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma
Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis
A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.
Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma
Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma
Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma
A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma
Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0)
Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy
Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases
Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver
BAP1 Testing in Instance Choroidal Nevi or Uveal Melanoma
Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma
|20||Not yet recruiting||
Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye
† Study has passed its completion date and status has not been verified in more than two years.